Viatris
As of the edition of 20 October 2026, Viatris runs 76 drugs, 66 of them marketed; it is on route A at 1 target and on route B at 27 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 34 company names in this family.
- Mylan Bertek Pharmaceuticals: acquired in 2020; successor Viatris Inc.
- Mylan Inc.: acquired in 2020; successor Viatris Inc.
- Mylan Institutional Inc: acquired in 2020; successor Viatris Inc.
- Mylan Institutional Llc A Viatris Co: acquired in 2020; successor Viatris Inc.
- Mylan Ireland Ltd: acquired in 2020; successor Viatris Inc.
- Mylan Pharmaceuticals Private Limited: acquired in 2020; successor Viatris Inc.
- Mylan Pharma UK Ltd.: acquired in 2020; successor Viatris Inc.
- Mylan Specialty Lp A Viatris Co: acquired in 2020; successor Viatris Inc.
- Mylan Technologies Inc.: acquired in 2020; successor Viatris Inc.
- Upjohn Manufacturing Ireland Unltd: acquired in 2020; successor Viatris Inc.
- Upjohn Us 2 Llc: acquired in 2020; successor Viatris Inc.
- Oyster Point Pharma, Inc.: acquired in 2023; successor Viatris Inc.
And 1 more.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 66 |
| Active | 3 |
| Went quiet | 4 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 76 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetaminophen | none listed | 17 |
| Atorvastatin | none listed | 4 |
| Celecoxib | none listed | 2 |
| Simvastatin | none listed | 3 |
| Amlodipine | none listed | 16 |
| Insulin glargine | Ended 2012 (computed from the first US licence) | 0 |
| Pregabalin | none listed | 2 |
| Remifentanil | none listed | 1 |
| Epinephrine | none listed | 23 |
| Sildenafil | Ends 2030 (exclusivity) | 3 |
| Hydrocortisone | none listed | 5 |
| Gabapentin | none listed | 1 |
| Albuterol | none listed | 2 |
| Estradiol | Ends 2032 (patent) | 6 |
| Varenicline | none listed | 1 |
| Vancomycin | none listed | 0 |
| Formoterol | none listed | 2 |
| Sertraline | none listed | 1 |
| Furosemide | none listed | 2 |
| Tretinoin | none listed | 3 |
| Clonidine | none listed | 0 |
| Methadone | none listed | 2 |
| Imiquimod | none listed | 2 |
| Venlafaxine | none listed | 1 |
| Fenofibrate | none listed | 3 |
A route B row is one company at one target. 41 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 1 target, route B at 27 targets.
All 28 rows on route A or B
In the product28 company-target rows on route A or B; 25 are not shown here, and no score is.
See all 28 targets where Viatris needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Lungs and airways: 18 trials led
- Immune system: 14 trials led
- Heart and blood vessels: 11 trials led